Key clinical point: For patients with Crohn’s disease, therapeutic drug monitoring helped identify early nonresponse to ustekinumab induction.
Major finding: At week 8, median trough ustekinumab levels were 6 mcg/mL in week 16 responders and 1.3 mcg/mL in week 16 nonresponders (P = .03). An ustekinumab trough level of 2.0 mcg/mL or higher distinguished responders from nonresponders with an area under the receiver operating curve of 0.75.
Study details: Prospective study of 51 patients with active luminal Crohn’s disease.
Disclosures: The researchers did not acknowledge external funding sources. Dr. Soufflet reported having no conflicts of interest. The senior author and three coinvestigators disclosed ties to MSD, AbbVie, Tillots, and several other pharmaceutical companies.
Soufflet N et al. Clin Gastroenterol Hepatol. 2019 Mar 6. doi: 10.1016/j.cgh.2019.02.042.